A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects
Latest Information Update: 02 May 2023
At a glance
- Drugs ACT-777991 (Primary)
- Indications Immunological disorders
- Focus Adverse reactions; First in man
- Sponsors Idorsia Pharmaceuticals
- 24 Mar 2023 Results presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 17 Jun 2022 Status changed from active, no longer recruiting to completed.
- 01 Jun 2022 Planned End Date changed from 1 May 2022 to 15 Jun 2022.